Buy & Sell Squarespace Inc (SQSP) – Squarespace Inc Price Today
Key Stats
- $6.47BMarket Cap
- TechnologySector
- -3M Drawdown
- $6.78BEnterprise Value
- -Dividend Yield
- 58 daysTypical Hold Time
Squarespace Inc (SQSP) is currently valued at a market capitalization of $6.47B, with an enterprise value of $6.78B. Over the past 52 weeks, Squarespace Inc has traded between a low of $27.6 and a high of $46.67, highlighting its annual price range. On average, investors hold Squarespace Inc for approximately 58 days, indicating typical investor behavior on the platform.
About Squarespace Inc
Squarespace is a provider of subscription-based website-building software and hosting services primarily servicing entrepreneurs and micro businesses. The company offers a range of add-on and standalone tools, including scheduling functionality, email marketing, member areas for paid content, and design tools for social media and video content. Following the 2021 acquisition of Tock, Squarespace has expanded into servicing hospitality customers with reservation, take-out, and event management software.
Most Recent News
Harvest Investment Services sells 356,000 shares of Adaptive Biotechnologies worth $5.7M
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...

Harbour BioMed wins $20.2M patent infringement verdict against Amgen, with potential damages tripling to $60.6M.
Harbour BioMed secured a unanimous jury verdict in Delaware, finding Amgen willfully infringed on its antibody discovery patent, awarding $20.2 million in damages. The verdict validates Harbour's proprietary technology and allows the company to seek ...

Ascentage Pharma reveals promising clinical data for olverembatinib and lisaftoclax in blood cancer treatments at EHA2026.
Ascentage Pharma presented 17 clinical updates on its key cancer drugs olverembatinib and lisaftoclax at the EHA2026 Congress, showing strong efficacy and safety in treating various blood cancers including chronic myeloid leukemia (CML) and Philadelp...
